Achieve Life Sciences (ACHV) Non Operating Income (2010 - 2026)
Achieve Life Sciences (ACHV) recorded quarterly Non Operating Income of -$13000.0 in Q1 2026, down 118.84% on a QoQ basis from $69000.0 in Q4 2025, and down 161.9% year-over-year from $21000.0 in Q1 2025.
Achieve Life Sciences (ACHV) Non Operating Income (2010 - 2026) Analysis & Trends
Achieve Life Sciences has disclosed Non Operating Income across 17 years of filings, most recently posting -$13000.0 for Q1 2026.
- Quarterly Non Operating Income fell 161.9% year-over-year to -$13000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $152000.0 (down 71.37% YoY) and the FY2025 annual result came in at $232000.0, up 873.33% from the prior year.
- Non Operating Income declined to -$13000.0 in Q1 2026, from $69000.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $1.2 million in Q4 2022 and troughed at -$2.5 million in Q4 2023.
- A 5-year average of -$154764.7 and a median of -$13000.0 in 2026 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2022 — Non Operating Income surged 3488.89% — and 2024, when it slumped 16966.67%.
- Tracing ACHV's Non Operating Income over 5 years: stood at $1.2 million in 2022, then tumbled by 308.11% to -$2.5 million in 2023, then soared by 121.98% to $558000.0 in 2024, then tumbled by 87.63% to $69000.0 in 2025, then sank by 118.84% to -$13000.0 in 2026.
- Business Quant data shows ACHV's Non Operating Income at -$13000.0 in Q1 2026, $69000.0 in Q4 2025, and $251000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 444,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 9.35 Mn |
| 10 | Achieve Life Sciences | 93.71 Mn | 63.22 Mn | - | -13,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13,000.00 |
| Dec 31, 2025 | 69,000.00 |
| Sep 30, 2025 | 251,000.00 |
| Jun 30, 2025 | -155,000.00 |
| Mar 31, 2025 | 21,000.00 |
| Dec 31, 2024 | 558,000.00 |
| Sep 30, 2024 | -46,000.00 |
| Jun 30, 2024 | -2,000.00 |
| Mar 31, 2024 | -512,000.00 |
| Dec 31, 2023 | -2.54 Mn |
| Sep 30, 2023 | -536,000.00 |
| Jun 30, 2023 | -525,000.00 |
| Mar 31, 2023 | -3,000.00 |
| Dec 31, 2022 | 1.22 Mn |
| Sep 30, 2022 | -30,000.00 |
| Jun 30, 2022 | -395,000.00 |
| Mar 31, 2022 | 6,000.00 |
| Dec 31, 2021 | -36,000.00 |
| Sep 30, 2021 | 2,000.00 |
| Jun 30, 2021 | -12,000.00 |